What was studied?
A randomized, double-blind phase 3 trial enrolled 667 adults with overweight or obesity without type 2 diabetes. Researchers compared oral semaglutide with placebo for 68 weeks, with lifestyle intervention in both groups.
What did the researchers report?
The active group had greater average weight reduction and more participants met the prespecified weight-loss threshold. The publication also assessed adverse events and tolerability of the studied formulation.
What are the limits?
Absorption and formulation are central to interpreting an oral-peptide trial. This is not evidence that raw peptide material can reproduce the pharmaceutical product, or that oral and other formulations are interchangeable. The defined eligibility and follow-up also limit generalization.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.